A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

Vernalis (R&D) Ltd50 enrolled

Overview

The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and arms, sometimes experienced by people with diabetes). An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) and/or Health Canada.

Diabetic Peripheral Neuropathic Pain (DPNP) is pain in your feet and legs, or even in your hands and arms, sometimes experienced by people with diabetes. Neuropathic pain syndromes are much more common than is perhaps generally recognized. Approximately 1% of the population in western countries suffers from neuropathic pain. Some clinical conditions are associated with a relatively high incidence of neuropathic pain. Approximately 15% of patients with diabetic neuropathy have persistent neuropathic pain in the feet, legs and hands.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Pain Diabetic Neuropathies

Interventions

V3381DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females 18-75 years of age * Diabetes mellitus (type I or type II) * No change in medications for reducing blood sugar within 4 weeks before screening * Experiencing daily pain due to diabetic neuropathy for at least 6 months but not more than 5 years * Neuropathic pain must begin in the feet, with relatively symmetrical onset. * Willing to perform self-monitoring of blood glucose * Able to communicate intelligibly with the investigator and study coordinator * Keeping all appointments for clinic visits, tests, and procedures Exclusion Criteria: * Any clinically significant neurologic disorders (with the exception of diabetic peripheral neuropathic pain) * Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study * Prior renal transplant or current renal dialysis * Pernicious anemia * Untreated hypothyroidism * Amputations due to diabetes mellitus (with the exception of toes) * Any clinically significant abnormal electrocardiogram (ECG) * Any history of cardiac arrhythmia * History of myocardial infarction * Active angina * Uncontrolled hypertension (i.e., \> 140/90 mm Hg) * Known or at high risk of hepatitis B or C infection * Known or at high risk of human immunodeficiency virus (HIV) infection * Any anticipated need for surgery during the study * Glycosylated hemoglobin (HbA1c) \> 9% * Known seizure disorder * Any malignancy in the past 2 years (with the exception of basal cell carcinoma) * Pain that cannot be clearly differentiated from, or conditions that interfere with the assessment of diabetic neuropathic pain. * Use of anticonvulsants, antidepressants, or prescription membrane-stabilizing agents * History of substance abuse or dependence within the past year, excluding nicotine and caffeine * Frequent and/or severe allergic reactions with multiple medications * Participation in any clinical trial within 30 days before screening

Locations (6)

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Clinical Research of West Florida, Inc.

Clearwater, Florida, United States

Translational Pain Research Group, Brigham & Women's Hospital

Boston, Massachusetts, United States

American Center for Clinical Trials

Southfield, Michigan, United States

Outcomes

Primary Outcomes

11 point numerical pain rating scale (NPRS) daily diary

Secondary Outcomes

Modified Brief Pain Inventory for DPN

McGill Pain Questionnaire - Short Form

Neuropathic Pain Symptom Inventory

Medical Outcomes Survey Short Form - 12, Version 2

Patient Global Impression of Change

Patient Preference Questionnaire (end of 2nd treatment period only)

Clinical Global Impression of Change

Additional secondary assessments will be included in the daily diary: consumption of rescue analgesics

daily sleep interference score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.